TauC3 Biologics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Series A
  • (Upcoming)

  • Latest Deal Amount
  • $25M

  • Investors
  • 9

TauC3 Biologics General Information

Description

Operator of a biopharmaceutical company intended to develop precision immunotherapies for the treatment of a subset of neurodegenerative diseases known as tauopathies. The company's technology is a humanized monoclonal antibody, uniquely targeting an especially noxious protein metabolite in the brain of patients with tau-related frontotemporal dementia and progressive supranuclear palsy, with the aim of halting or preventing the onset of disease, enabling patients to get a sustainable, healthy life with the treatment for their fatal disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Stevenage Bioscience Catalyst
  • Gunnels Wood Road
  • Stevenage SG1 2FX
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Stevenage Bioscience Catalyst
  • Gunnels Wood Road
  • Stevenage SG1 2FX
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TauC3 Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series A) $25M Upcoming Pre-Clinical Trials
6. Later Stage VC Completed Pre-Clinical Trials
5. Seed Round Completed Pre-Clinical Trials
4. Seed Round 31-Mar-2022 Completed Pre-Clinical Trials
3. Seed Round 28-Dec-2020 Completed Pre-Clinical Trials
2. Angel (individual) 02-Nov-2020 $148K $148K Completed Pre-Clinical Trials
1. Spin-Off 19-Jul-2019 Completed Startup
To view TauC3 Biologics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

TauC3 Biologics Patents

TauC3 Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3135170-A1 Anti-tauc3 antibodies and uses thereof Pending 05-Apr-2019
EP-3946605-A1 Anti-tauc3 antibodies and uses thereof Pending 05-Apr-2019
US-11155609-B2 Anti-tauc3 antibodies and uses thereof Active 05-Apr-2019
US-12162930-B2 Anti-tauc3 antibodies and uses thereof Active 05-Apr-2019
US-20200407431-A1 Anti-tauc3 antibodies and uses thereof Active 05-Apr-2019 C07K16/18
To view TauC3 Biologics’s complete patent history, request access »

TauC3 Biologics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TauC3 Biologics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
Angel (individual) Minority
Joseph Ventures Family Office Minority
Northlea Partners Venture Capital Minority
Angel (individual) Minority
You’re viewing 5 of 9 investors. Get the full list »

TauC3 Biologics FAQs

  • When was TauC3 Biologics founded?

    TauC3 Biologics was founded in 2019.

  • Where is TauC3 Biologics headquartered?

    TauC3 Biologics is headquartered in Stevenage, United Kingdom.

  • What is the size of TauC3 Biologics?

    TauC3 Biologics has 6 total employees.

  • What industry is TauC3 Biologics in?

    TauC3 Biologics’s primary industry is Drug Discovery.

  • Is TauC3 Biologics a private or public company?

    TauC3 Biologics is a Private company.

  • What is TauC3 Biologics’s current revenue?

    The current revenue for TauC3 Biologics is .

  • How much funding has TauC3 Biologics raised over time?

    TauC3 Biologics has raised $6.56M.

  • Who are TauC3 Biologics’s investors?

    , , Joseph Ventures, Northlea Partners, and are 5 of 9 investors who have invested in TauC3 Biologics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process